• TOP
  • 研究と業績
  • 業績

RESEARCH ACTIVITY

研究と業績

業績

2021年

原著(欧文)

  • 1. Shinozaki M, Yasui-Furukori N, Adachi N, Ueda H, Hongo S, Azekawa T, Kubota Y, Katsumoto E, Edagawa K, Goto E, Miki K, Kato M, Nakagawa A, Kikuchi T, Tsuboi T, Watanabe K, Shimoda K, Yoshimura R. Differences in prescription patterns between real-world outpatients with bipolar I and II disorders in the MUSUBI survey. Asian J Psychiatr. 2021;67:102935.
  • 2. Furihata R, Otsuki R, Hasegawa N, Tsuboi T, Numata S, Yasui-Furukori N, Kashiwagi H, Hori H, Ochi S, Muraoka H, Onitsuka T, Komatsu H, Takeshima M, Hishimoto A, Nagasawa T, Takaesu Y, Nakamura T, Asami T, Miura K, Matsumoto J, Ohi K, Yasuda Y, Iida H, Ogasawara K, Hashimoto N, Ichihashi K, Yamada H, Watanabe K, Inada K, Hashimoto R. Hypnotic medication use among inpatients with schizophrenia and major depressive disorder: results of a nationwide study. Sleep Med. 2021;89:23-30.
  • 3. Sugawara N, Yasui-Furukori N, Fukushima A, Shimoda K. Attitudes of Medical Students toward COVID-19 Vaccination: Who Is Willing to Receive a Third Dose of the Vaccine? Vaccines (Basel). 2021;9(11):1295.
  • 4. Takeuchi H, Takekita Y, Hori H, Oya K, Miura I, Hashimoto N, Yasui-Furukori N. Pharmacological treatment algorithms for the acute phase, agitation, and maintenance phase of first-episode schizophrenia: Japanese Society of Clinical Neuropsychopharmacology treatment algorithms. Hum Psychopharmacol. 2021;36(6):e2804.
  • 5. Komahashi-Sasaki H, Yasui-Furukori N, Sasaki T, Shinozaki M, Hayashi Y, Kato K, Inoue Y, Tsuchimine S, Watanabe T, Sugawara N, Shimoda K. Effects of CYP2D6 Genotypes on Venlafaxine Metabolism in Japanese Psychiatric Patients With Depression. Ther Drug Monit. 2021;43(5):681-687.
  • 6. Konno Y, Fujino Y, Ikenouchi A, Adachi N, Kubota Y, Azekawa T, Ueda H, Edagawa K, Katsumoto E, Goto E, Hongo S, Kato M, Tsuboi T, Yasui-Furukori N, Nakagawa A, Kikuchi T, Watanabe K, Yoshimura R. Relationship Between Mood Episode and Employment Status of Outpatients with Bipolar Disorder: Retrospective Cohort Study from the Multicenter Treatment Survey for Bipolar Disorder in Psychiatric Clinics (MUSUBI) Project. Neuropsychiatr Dis Treat. 2021;17:2867-2876.
  • 7. Hashimoto N, Yasui-Furukori N, Hasegawa N, Ishikawa S, Numata S, Hori H, Iida H, Ichihashi K, Furihata R, Murata A, Tsuboi T, Takeshima M, Kyou Y, Komatsu H, Kubota C, Ochi S, Takaesu Y, Usami M, Nagasawa T, Hishimoto A, Miura K, Matsumoto J, Ohi K, Yamada H, Inada K, Watanabe K, Shimoda K, Hashimoto R. Characteristics of discharge prescriptions for patients with schizophrenia or major depressive disorder: Real-world evidence from the Effectiveness of Guidelines for Dissemination and Education (EGUIDE) psychiatric treatment project. Asian J Psychiatr. 2021;63:102744.
  • 8. Tasaki M, Yasui-Furukori N, Yokoyama S, Shinozaki M, Sugawara N, Shimoda K. Hypoprolactinemia and hyperprolactinemia in male schizophrenia patients treated with aripiprazole and risperidone and their relationships with testosterone levels. Neuropsychopharmacol Rep. 2021;41(3):379-384.
  • 9. Tasaki M, Yasui-Furukori N, Kubo K, Yokoyama S, Shinozaki M, Sugawara N, Inoue Y, Shimoda K. Relationship of Prolactin Concentrations to Steady-State Plasma Concentrations of Aripiprazole in Patients With Schizophrenia. Ther Drug Monit. 2021;43(4):589-592.
  • 10. Kawamata Y, Sugawara N, Ishioka M, Kubo K, Suzuki K, Fujii A, Furukori H, Nakagami T, Yasui-Furukori N, Shimoda K. Different Attitudes of Patients and Psychiatrists Toward Benzodiazepine Treatment. Neuropsychiatr Dis Treat. 2021;17:1927-1936.
  • 11. Numata S, Nakataki M, Hasegawa N, Takaesu Y, Takeshima M, Onitsuka T, Nakamura T, Edagawa R, Edo H, Miura K, Matsumoto J, Yasui-Furukori N, Kishimoto T, Hori H, Tsuboi T, Yasuda Y, Furihata R, Muraoka H, Ochi S, Nagasawa T, Kyou Y, Murata A, Katsumoto E, Ohi K, Hishimoto A, Inada K, Watanabe K, Hashimoto R. Improvements in the degree of understanding the treatment guidelines for schizophrenia and major depressive disorder in a nationwide dissemination and implementation study. Neuropsychopharmacol Rep. 2021;41(2):199-206.
  • 12. Sasaki T, Yasui-Furukori N, Komahashi-Sasaki H, Shinozaki M, Hayashi Y, Kato K, Inoue Y, Tsuchimine S, Watanabe T, Sugawara N, Shimoda K. CYP2D6*10 polymorphism and the enantioselective O-desmethylation of S-(+)- and R-(-)-venlafaxine in Japanese psychiatric patients. Basic Clin Pharmacol Toxicol. 2021;128(5):677-685.
  • 13. Sugawara N, Yasui-Furukori N, Shimoda K. Projections of psychiatrists' distribution for patients in Japan: a utilization-based approach. Hum Resour Health. 2021 Apr 9;19(1):49.
  • 14. Sakurai H, Yasui-Furukori N, Suzuki T, Uchida H, Baba H, Watanabe K, Inada K, Kikuchi YS, Kikuchi T, Katsuki A, Kishida I, Kato M. Pharmacological Treatment of Schizophrenia: Japanese Expert Consensus. Pharmacopsychiatry. 2021;54(2):60-67.
  • 15. Adachi N, Azekawa T, Edagawa K, Goto E, Hongo S, Kato M, Katsumoto E, Kikuchi T, Kubota Y, Miki K, Nakagawa A, Tsuboi T, Ueda H, Watanabe K, Watanabe Y, Yasui-Furukori N, Yoshimura R. Estimated model of psychotropic polypharmacy for bipolar disorder: Analysis using patients' and practitioners' parameters in the MUSUBI study. Hum Psychopharmacol. 2021;36(2):e2764.
  • 16. Tokumitsu K, Yasui-Furukori N, Takeuchi J, Yachimori K, Sugawara N, Terayama Y, Tanaka N, Naraoka T, Shimoda K. The combination of MMSE with VSRAD and eZIS has greater accuracy for discriminating mild cognitive impairment from early Alzheimer's disease than MMSE alone. PLoS One. 2021;16(2):e0247427.
  • 17. Okayasu H, Shinozaki T, Takano Y, Sugawara N, Fujii K, Yasui-Furukori N, Ozeki Y, Shimoda K. Effects of Antipsychotics on Arrhythmogenic Parameters in Schizophrenia Patients: Beyond Corrected QT Interval. Neuropsychiatr Dis Treat. 2021;17:239-249.
  • 18. Funaba M, Kawanishi H, Fujii Y, Higami K, Tomita Y, Maruo K, Sugawara N, Oe Y, Kura S, Horikoshi M, Ohara C, Kikuchi H, Ariga H, Fukudo S, Sekiguchi A, Ando T. Hybrid Cognitive Behavioral Therapy With Interoceptive Exposure for Irritable Bowel Syndrome: A Feasibility Study. Front Psychiatry. 2021;12:673939.
  • 19. Matsuo K, Kono K, Shimoda K, Kaji Y, Akiyama K. Reproducibility of the lateralization index in functional magnetic resonance imaging across language tasks. Journal of Neurolinguistics. 57: Article 100943.

症例報告(欧文)

  • 1. Maehara R, Kawamata Y, Ichikawa M, Mitani K, Yasui-Furukori N, Shimoda K. Suicide attempt induced by drug-induced leukoencephalopathy: A case report. Neuropsychopharmacol Rep. 2021 Dec;41(4):551-553.
  • 2. Okayasu H, Yasui-Furukori N, Shimoda K. A pregnant woman who experienced auditory hallucinations concurrent with hyperemesis gravidarum: A case report. Neuropsychopharmacol Rep. 2021 Dec;41(4):548-550.
  • 3. Yokoyama S, Sugisaki T, Ryota Y, Yoshiteru S, Okayasu H, Shioda M, Suzuki K, Yasui-Furukori N, Shimoda K. Transient glyphosate encephalopathy due to a suicide attempt. Neuropsychopharmacol Rep. 2021 Sep;41(3):444-447.
  • 4. Kikuchi K, Yasui-Furukori N, Hasegawa C, Watahiki M, Inoue T, Shimoda K. Takotsubo cardiomyopathy after hypoglycemia in a patient with anorexia nervosa. Ann Gen Psychiatry. 2021 Sep 4;20(1):39.
  • 5. Tokumitsu K, Oyama S, Takeuchi J, Yachimori K, Sugawara N, Yasui-Furukori N, Shimoda K. Heidenhain variant of Creutzfeldt-Jakob disease resembles dementia with Lewy bodies. Psychogeriatrics. 2021 Jan;21(1):121-124.

総説

  • 1. 篠﨑 將貴, 佐々木 太郎, 佐々木 はづき, 古郡 規雄, 下田 和孝. 向精神薬の薬物代謝・動態に関する基礎知識. 臨床精神薬理. 2021. 24. 2. 117-123
  • 2. 古郡 規雄, 西村 勝治, 久住 一郎, 新津 富央, 稲田 健, 上野 雄文, 木下 利彦, 三村 將, 中込 和幸, 下田 和孝, 橋本亮太. クロザピンモニタリング制度に関する学会での活動. 臨床精神薬理. 2021. 24. 3. 295-302
  • 3. 古郡 規雄, 橋本亮太. クロザピンモニタリング制度の現在と未来. 臨床精神薬理. 2021. 24. 3. 215-220.
  • 4. 古郡 規雄, 下田 和孝. 高齢者併存疾患患者における抗うつ薬の臨床薬理. 臨床薬理 2021.52(3):85-88.
  • 5. 古郡 規雄, 下田 和孝. 精神科臨床における薬物動態と薬物相互作用. 日本精神薬学会会誌 2021. 4(2):10-13.
  • 6. 佐藤由英, 古郡 規雄, 下田 和孝. アルツハイマー型認知症への抗認知症薬はどう選ぶ? 同種・同効薬の使い分け 2021. 63(7): 287-294.
  • 7. 菊池昂太, 古郡 規雄, 下田 和孝. 糖尿病の栄養指導Q&A. 統合失調症. 糖尿病プラクティス. 2021. 38(4):487-488.
  • 8. 佐藤葵, 古郡 規雄, 佐藤由英, 下田 和孝. 糖・脂質代謝異常. 精神科治療学36巻増刊号
  • 9. 佐藤葵, 佐藤由英, 古郡 規雄, 下田 和孝. 向精神薬の合剤の可能性について. 臨床精神薬理2021, 24(6), 619-623.
  • 10. 大和田環, 古郡 規雄, 下田 和孝. 糖尿病. 精神疾患の悪化と間違えやすい身体の問題. 精神科. 2021, 39(6), 720-724.

科研費

  • 基盤研究C 古郡規雄
    24時間持続血糖を用いた統合失調症患者の予後改善の試み
    1,560千円 (直接経費: 1,200千円、間接経費: 360千円)
  • 基盤研究C 藤平明広
    統合失調症罹患者におけるフレイルの実態と発症要因に関する研究
    1,300千円 (直接経費: 1,000千円、間接経費: 300千円)
  • 基盤研究C 徳満敬大
    女性の評価にもとづく男性周産期うつ病の新規スクリーニングシステムの開発
    1,560千円 (直接経費: 1,200千円、間接経費: 360千円)
  • 若手研究 岡安寛明
    心拍変動・瞬時心拍変動に着目した向精神薬による精神疾患患者の突然死予防戦略
    1,170千円 (直接経費: 900千円、間接経費: 270千円)
  • 若手研究 佐々木はづき
    CYP遺伝子多型に焦点をあてたベンラファキシンの薬物動態解析
    1,170千円 (直接経費: 900千円、間接経費: 270千円)

2020年

原著(欧文)

  • 1. Sugawara N, Yasui-Furukori N, Tsuji T, Hayashi S, Ajisawa Y, Ochiai T, Imagawa H, Shimoda K. The Relationship Between Baseline Clinical Symptom Characteristics and Working Ability in Japanese Patients Treated for Major Depressive Disorder and Painful Physical Symptoms. Neuropsychiatr Dis Treat. 2020 Dec 11;16:3063-3070. doi: 10.2147/NDT.S274608. eCollection 2020.
  • 2. Tokumitsu K, Yasui-Furukori N, Adachi N, Kubota Y, Watanabe Y, Miki K, Azekawa T, Edagawa K, Katsumoto E, Hongo S, Goto E, Ueda H, Kato M, Yoshimura R, Nakagawa A, Kikuchi T, Tsuboi T, Shimoda K, Watanabe K. Real-world clinical features of and antidepressant prescribing patterns for outpatients with bipolar disorder. BMC Psychiatry. 2020 Nov 23;20(1):555. doi: 10.1186/s12888-020-02967-5
  • 3. Yasui-Furukori N, Adachi N, Kubota Y, Azekawa T, Goto E, Edagawa K, Katsumoto E, Hongo S, Ueda H, Miki K, Kato M, Yoshimura R, Nakagawa A, Kikuchi T, Tsuboi T, Watanabe K, Shimoda K. Factors Associated with Doses of Mood Stabilizers in Real-world Outpatients with Bipolar Disorder. Clin Psychopharmacol Neurosci. 2020 Nov 30;18(4):599-606. doi: 10.9758/cpn.2020.18.4.599.
  • 4. Adachi N, Azekawa T, Edagawa K, Goto E, Hongo S, Kato M, Katsumoto E, Kikuchi T, Kubota Y, Miki K, Nakagawa A, Tsuboi T, Ueda H, Watanabe K, Watanabe Y, Yasui-Furukori N, Yoshimura R. Estimated model of psychotropic polypharmacy for bipolar disorder: Analysis using patients' and practitioners' parameters in the MUSUBI study. Hum Psychopharmacol. 2020 Oct 22:e2764. doi: 10.1002/hup.2764. Online ahead of print.
  • 5. Sugawara N, Yasui-Furukori N, Yamazaki M, Shimoda K, Mori T, Sugai T, Matsuda H, Suzuki Y, Ozeki Y, Okamoto K, Sagae T, Someya T. Predictive Utility of Body Mass Index for Metabolic Syndrome Among Patients with Schizophrenia in Japan. Neuropsychiatr Dis Treat. 2020 Sep 30;16:2229-2236. doi: 10.2147/NDT.S269619. eCollection 2020.
  • 6. Kato M, Adachi N, Kubota Y, Azekawa T, Ueda H, Edagawa K, Katsumoto E, Goto E, Hongo S, Tsuboi T, Yasui-Furukori N, Yoshimura R, Nakagawa A, Kikuchi T, Kinoshita T, Watanabe Y, Miki K, Watanabe K. Clinical features related to rapid cycling and one-year euthymia in bipolar disorder patients: A multicenter treatment survey for bipolar disorder in psychiatric clinics (MUSUBI). J Psychiatr Res. 2020 Dec;131:228-234. doi: 10.1016/j.jpsychires.2020.09.030. Epub 2020 Sep 30.
  • 7. Sugawara N, Yasui-Furukori N, Sayama M, Shimoda K. Factor structure of the University Personality Inventory in Japanese medical students. BMC Psychol. 2020 Oct 1;8(1):103. doi: 10.1186/s40359-020-00469-3.
  • 8. Takata K, Oniki K, Tateyama Y, Yasuda H, Yokota M, Yamauchi S, Sugawara N, Yasui-Furukori N, Saruwatari J. The associations of the number of medications and the use of anticholinergics with recovery from tubal feeding: a longitudinal hospital-based study. BMC Geriatr. 2020 Sep 29;20(1):373. doi: 10.1186/s12877-020-01778-3.
  • 9. Iida H, Iga J, Hasegawa N, Yasuda Y, Yamamoto T, Miura K, Matsumoto J, Murata A, Ogasawara K, Yamada H, Hori H, Ichihashi K, Hashimoto N, Ohi K, Yasui-Furukori N, Tsuboi T, Nakamura T, Usami M, Furihata R, Takaesu Y, Iwamoto K, Sugiyama N, Kishimoto T, Tsujino N, Yamada H, Hishimoto A, Nemoto K, Atake K, Muraoka H, Katsumoto E, Oishi S, Inagaki T, Ito F, Imamura Y, Kido M, Nagasawa T, Numata S, Ochi S, Iwata M, Yamamori H, Fujita J, Onitsuka T, Yamamura S, Makinodan M, Fujimoto M, Takayanagi Y, Takezawa K, Komatsu H, Fukumoto K, Tamai S, Yamagata H, Kubota C, Horai T, Inada K, Watanabe K, Kawasaki H, Hashimoto R. Unmet needs of patients with major depressive disorder - Findings from the 'Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE)' project: A nationwide dissemination, education, and evaluation study. Psychiatry Clin Neurosci. 2020 Dec;74(12):667-669. doi: 10.1111/pcn.13143. Epub 2020 Oct 9..
  • 10. Sakurai H, Kato M, Yasui-Furukori N, Suzuki T, Baba H, Watanabe K, Inada K, Kishida I, Sugawara Kikuchi Y, Kikuchi T, Katsuki A, Uchida H; Medical Education Panel of the Japanese Society of Clinical Neuropsychopharmacology. Pharmacological management of bipolar disorder: Japanese expert consensus. Bipolar Disord. 2020 Dec;22(8):822-830. doi: 10.1111/bdi.12959. Epub 2020 Jul 2.
  • 11. Yokoyama S, Yasui-Furukori N, Nakagami T, Miyazaki K, Ishioka M, Tarakita N, Kubo K, Sugawara N, Shimoda K. Association Between the Serum Carnitine Level and Ammonia and Valproic Acid Levels in Patients with Bipolar Disorder. Ther Drug Monit. 2020 Oct;42(5):766-770. doi: 10.1097/FTD.0000000000000778.
  • 12. Sugawara N, Yasui-Furukori N, Maruo K, Shimoda K, Sumiyoshi T. Working status of caregivers for people with dementia: Analysis data from a Japanese Nationwide Survey. PLoS One. 2020 May 29;15(5):e0232787. doi: 10.1371/journal.pone.0232787. eCollection 2020.
  • 13. Tsuboi T, Suzuki T, Azekawa T, Adachi N, Ueda H, Edagawa K, Katsumoto E, Kubota Y, Goto E, Hongo S, Watanabe Y, Kato M, Yasui-Furukori N, Yoshimura R, Nakagawa A, Kikuchi T, Watanabe K. Factors Associated with Non-Remission in Bipolar Disorder: The Multicenter Treatment Survey for Bipolar Disorder in Psychiatric Outpatient Clinics (MUSUBI). Neuropsychiatr Dis Treat. 2020 Mar 31;16:881-890. doi: 10.2147/NDT.S246136. eCollection 2020.
  • 14. Sakurai H, Uchida H, Kato M, Suzuki T, Baba H, Watanabe K, Inada K, Kikuchi T, Katsuki A, Kishida I, Sugawara Kikuchi Y, Yasui-Furukori N; Medical Education Panel of the Japanese Society of Clinical Neuropsychopharmacology. Pharmacological management of depression: Japanese expert consensus. J Affect Disord. 2020 Apr 1;266:626-632. doi: 10.1016/j.jad.2020.01.149. Epub 2020 Jan 28.
  • 15. Murakami H, Yasui-Furukori N, Otaka H, Nakayama H, Murabayashi M, Mizushiri S, Matsumura K, Tanabe J, Matsuhashi Y, Yanagimachi M, Sugawara N, Shimoda K, Daimon M. Coping styles associated with glucose control in individuals with type 2 diabetes mellitus. J Diabetes Investig. 2020 Sep;11(5):1215-1221. doi: 10.1111/jdi.13225. Epub 2020 Mar 8.
  • 16. Yasui-Furukori N, Murakami H, Otaka H, Tanabe J, Yanagimachi M, Murabayashi M, Matsumura K, Matsuhashi Y, Nakayama H, Mizushiri S, Sugawara N, Daimon M, Shimoda K. Personality Traits Do Not Have Influence on Glycemic Control in Outpatients with Type 2 Diabetes Mellitus. Psychiatry Investig. 2020 Jan;17(1):78-84. doi: 10.30773/pi.2019.0210. Epub 2020 Jan 25.
  • 17. Sugai T, Suzuki Y, Yamazaki M, Sugawara N, Yasui-Furukori N, Shimoda K, Mori T, Ozeki Y, Matsuda H, Okamoto K, Sagae T, Someya T. Lower Prolactin Levels in Patients Treated With Aripiprazole Regardless of Antipsychotic Monopharmacy or Polypharmacy. J Clin Psychopharmacol. 2020 Jan/Feb;40(1):14-17. doi: 10.1097/JCP.0000000000001158.

症例報告(欧文)

  • 1. Kikuchi K, Yasui-Furukori N, Yokoyama S, Hasegawa C, Kokubun A, Katsukura S, Shimizu T, Shimoda K. Clozapine-associated severe eosinophilia following lithium rebound neutropenia: A case report. Neuropsychopharmacol Rep. 2020 Dec;40(4):388-391. doi: 10.1002/npr2.12143. Epub 2020 Sep 19.
  • 2. Sato Y, Shinozaki M, Sasaki H, Shiinoki M, Shimizu T, Yasui-Furukori N, Shimoda K. Gluten-Related Disorder and Lactose Intolerance Concomitant With Avoidant/Restrictive Food Intake Disorder. Prim Care Companion CNS Disord. 2020 Jul 2;22(4):19l02517. doi: 10.4088/PCC.19l02517.
  • 3. Okayasu H, Yasui-Furukori N, Kadowaki T, Funakoshi K, Hirata K, Shimoda K. Bickerstaff's Brainstem Encephalitis Suspected as Functional Neurologic Disorders. Int Med Case Rep J. 2020 May 18;13:177-181. doi: 10.2147/IMCRJ.S249818. eCollection 2020.
  • 4. Takayasu S, Kamba A, Yoshida K, Terui K, Watanuki Y, Ishigame N, Mizushiri S, Tomita T, Nakamura K, Yasui-Furukori N, Daimon M. Secondary oxalosis induced by xylitol concurrent with lithium-induced nephrogenic diabetes insipidus: a case report. BMC Nephrol. 2020 May 1;21(1):157. doi: 10.1186/s12882-020-01814-9.
  • 5. Sato Y, Shinozaki M, Okayasu H, Yasui-Furukori N, Shimoda K. Successful Treatment With Lithium in a Refractory Patient With Periodic Catatonic Features: A Case Report. Clin Neuropharmacol. 2020 May/Jun;43(3):84-85. doi: 10.1097/WNF.0000000000000390.

総説

  • 1. Yasui-Furukori N, Shimoda K. Recent trends in antipsychotic polypharmacy in the treatment of schizophrenia. Neuropsychopharmacol Rep. 2020 Sep;40(3):208-210. doi: 10.1002/npr2.12127. Epub 2020 Jul 16.
  • 2. Tokumitsu K, Sugawara N, Maruo K, Suzuki T, Yasui-Furukori N, Shimoda K. Prevalence of perinatal depression among Japanese men: a meta-analysis. Ann Gen Psychiatry. 2020 Nov 18;19(1):65. doi: 10.1186/s12991-020-00316-0.
  • 3. Tokumitsu K, Sugawara N, Maruo K, Suzuki T, Shimoda K, Yasui-Furukori N. Prevalence of perinatal depression among Japanese women: a meta-analysis. Ann Gen Psychiatry. 2020 Jun 26;19:41. doi: 10.1186/s12991-020-00290-7. eCollection 2020.
  • 4. 竹内祥貴,古郡規雄,下田和孝. ドラッグデリバリーシステム. 臨床に役立つ基礎薬理学の用語解説. 臨床精神薬理. 23、943-944、2020.
  • 5. 古郡規雄、内田裕之、水野裕也、橋本亮太. クロザピン患者モニタリングサービスの国際比較-COVID-19対応を含めて-. 臨床精神薬理23、1041-1049、2020.
  • 6. 古郡規雄、田崎みなみ、古川葵、佐藤由英、横山沙安也、下田和孝. 抗うつ薬の使い分け 類似薬の使い分け改訂第3版. 199-217、2020.
  • 7. 徳満敬大、菅原典夫、古郡規雄、下田和孝. 日本人男性の周産期うつ病の心理的側面. 臨床精神医学 49、925-931、2020.
  • 8. 古郡規雄、下田和孝. 双極性障害薬物治療ガイドラインの変遷. 日精診誌ジャーナル、46、351-357、2020.
  • 9. 田﨑みなみ、古郡規雄、下田和孝. ロナセンテープの薬物動態. 臨床精神薬理. 23:249-254、2020.
  • 10. 竹内祥貴,古郡規雄,下田和孝. 薬物療法の気になる進歩. 精神科. 36:65-69、2020

科研費

  • 若手研究 岡安寛明
    心拍変動・瞬時心拍変動に着目した向精神薬による精神疾患患者の突然死予防戦略
    650千円 (直接経費: 500千円、間接経費: 150千円)
  • 若手研究 佐々木はづき
    CYP遺伝子多型に焦点をあてたベンラファキシンの薬物動態解析
    1,170千円 (直接経費: 900千円、間接経費: 270千円)

2019年

原著(欧文)

  • 1. Yokoyama N, Shiraki R, Watanabe T, Shiinoki M, Nin M, Shimizu T, Yasui-Furukori N, Shimoda K. Difficult differentiation of a somatic symptom disorder from anterior cutaneous nerve entrapment syndrome (ACNES): a case report. BMC Psychiatry. 2019 Dec 12;19(1):394.
  • 2. Shinozaki M, Pierce J, Hayashi Y, Watanabe T, Sasaki T, Komahashi-Sasaki H, Akiyama K, Kato K, Inoue Y, Tsuchimine S, Yasui-Furukori N, Ozeki Y, Shimoda K. 8-Hydroxylation and Glucuronidation of Mirtazapine in Japanese Psychiatric Patients: Significance of the Glucuronidation Pathway of 8-Hydroxy-Mirtazapine. Pharmacopsychiatry. 2019 Sep;52(5):237-244.
  • 3. Takeda K, Sugawara N, Yamada Y, Nagata T, Kashiwagi H, Kono T, Hirabayashi N, Okada T. Employment-Related Factors of Forensic Psychiatric Outpatients with Psychotic Disorders. Neuropsychiatr Dis Treat. 2019;15:3341-3350.
  • 4. Yasui-Furukori N, Murakami H, Otaka H, Nakayama H, Murabayashi M, Mizushiri S, Matsumura K, Tanabe J, Matsuhashi Y, Yanagimachi M, Nakamura K, Daimon M, Sugawara N. Coping behaviors and depressive status in individuals with type 2 diabetes mellitus. Ann Gen Psychiatry. 2019;18:11.
  • 5. Yasui-Furukori N, Murakami H, Otaka H, Nakayama H, Murabayashi M, Mizushiri S, Matsumura K, Tanabe J, Matsuhashi Y, Yanagimachi M, Nakamura K, Daimon M, Sugawara N. Personality associated with depressive status in individuals with type 2 diabetes mellitus. Neuropsychiatr Dis Treat. 2019;15:1133-1139.
  • 6. Okayasu H, Ozeki Y, Fujii K, Takano Y, Shinozaki T, Ohrui M, Shimoda K.
    Investigation of the Proarrhythmic Effects of Antidepressants according to QT Interval, QT Dispersion and T Wave Peak-to-End Interval in the Clinical Setting.
    Psychiatry Investig. 2019 Feb;16(2):159-166. https://doi.org/10.30773/pi.2018.12.11
  • 7. Akiyama K, Saito A, Saito S, Ozeki Y, Watanabe T, Fujii K, Shimoda K.
    Association of Genetic Variants at 22q11.2 Chromosomal Region with Cognitive Performance in Japanese Patients with Schizophrenia.
    Schizophrenia Research 2019 Mar 26; 17:100134. doi: 10.1016/j.scog.2019.100134. eCollection 2019 Sep.

総説

  • 1. 古郡規雄,下田和孝. リアルワールドエビデンスの重要性──展望について 臨床精神薬理. 22:1147-1151、2019
  • 2. 古郡規雄,藤平明広,下田和孝. 肥満者に対する精神科薬物治療. 臨床精神薬理. 22:1213-1217、2019
  • 3. 古郡規雄,下田和孝. 精神科における個別化医療を目指して. 臨床家からの視点. 薬局. 70:2537-2542、2019
  • 4. 古郡規雄. 抗精神病薬による代謝異常 精神科治療学 34:501-505、2019
  • 5. 菅原典夫, 古郡規雄, 下田和孝. 研究者からみた臨床研究法の課題. 精神科. 2019;35(5):440-443.

著書

  • 1. 新見正則、古郡規雄
    フローチャートメンタル漢方薬 臨床精神薬理学の第一人者が教えます!
    新興医学出版社 (2019.4)

2018年

原著(欧文)

  • 1. Tanaka H, Ehara A, Nakadate K, Yoshimoto K, Shimoda K, Ueda S.
    Behavioral, hormonal, and neurochemical outcomes of neonatal repeated shaking brain injury in adult rats.
    Physiology and Behavior Physiol Behav. 2019 Feb 1; 199:118-126. doi: 10.1016/j.physbeh.2018.11.025. Epub 2018 Nov 19.
  • 2. Kawamata Y, Ehara A, Yamaguchi T, Seo Y, Shimoda K, Ueda S.
    Repeated mild shaking of neonates induces transient cerebral microhemorrhages and anxiety-related behavior in adult rats.
    Neurosci Lett. 2018 Sep 25; 684:29-34. doi: 10.1016/j.neulet.2018.06.059. Epub 2018 Jul 2.
  • 3. Ogata H, Ihara H, Gito M, Sayama M, Murakami N, Ayabe T, Oto Y, Nagai T, Shimoda K.
    Aberrant, autistic, and food-related behaviors in adults with Prader-Willi syndrome. The comparison between young adults and adults.
    Research in Developmental Disabilities. 73:126-134, 2018. doi: 10.1016/j.ridd.2017.12.020. Epub 2018 Jan 8
  • 4. Ono S, Sugai T, Suzuki Y, Yamazaki M, Shimoda K, Mori T, Ozeki Y, Matsuda H, Sugawara N, Yasui-Furukori N, Okamoto K, Sagae T, Someya T.
    High-density lipoprotein-cholesterol and antipsychotic medication in overweight inpatients with schizophrenia: post-hoc analysis of a Japanese nationwide survey.
    BMC Psychiatry 18(1):180, 2018 doi: 10.1186/s12888-018-1764-1.
  • 5. Sugawara N, Sagae T, Yasui-Furukori N, Yamazaki M, Shimoda K, Mori T, Sugai T, Matsuda H, Suzuki Y, Ozeki Y, Okamoto K, Someya T.
    Effect of nutritional education on weight change and metabolic abnormalities among patients with schizophrenia in Japan: A randomized controlled trial.
    Journal of Psychiatric Research, 2018 Feb;97:77-83. doi: 10.1016/j.jpsychires.2017.12.002. Epub 2017 Dec 5.
  • 6. Sugawara N, Maruo K, Sugai T, Suzuki Y, Ozeki Y, Shimoda K, Someya T, Ysui-Furukori N.
    Prevalence of underweight in ptients with schizophrenia: A meta-analysis Schizophrenia research.
    195:67-73, 2018. doi: 10.1016/j.schres.2017.10.017. Epub 2017 Oct 17.
  • 7. Amare AT, Schubert KO, Hou L, Clark SR, Papiol S, Heilbronnerv U, Degenhardt F, Tekola-Ayele F, Hsu YH, Shekhtman T, Adli M, Akula N, Akiyama K, Ardau R, Arias B, Aubry JM, Backlund L, Bhattacharjee AK, Bellivier F, Benabarre A, Bengesser S, Biernacka JM, Birner A, Brichant-Petitjean C, Cervantes P, Chen HC, Chillotti C, Cichon S, Colom F, Cruceanu C, Czerski PM, Dalkner N, Dayer A, Zompo MD, DePaulo JR, Étain B, Falkai P, Forstner AJ, Frisen L, Frye MA, Fullerton JM, Gard S, Garnham JS, Goes FS, Grigoroiu-Serbanescu M, Grof P, Hashimoto R, Hauser J, Herms S, Hoffmann P, Hofmann A, Jamain S, Jiménez E, Kahn JP, Kassem L, Kato T, Kelsoe J, Kittel-Schneider S, Kliwicki S, König B, Kusumi I, Laje G, Landén M, Lavebratt C, Leboyer M, Leckband SG, Maj M, Manchia M, Martinsson L, McCarthy MJ, McElroy S, Mitchell PB, Mitjans M, Mondimore FM, Monteleone P, Nievergelt CM, Nöthen MM, Novák T, O’Donovan C, Ozaki N, Ösby U, Pfennig A, Potash JB, Reif A, Reininghaus E, Rouleau GA, Rybakowski JK, Schalling M, Schofield PR, Schweizer BW, Severino G, Shilling PD, Shimoda K, Simhandl C, Slaney CM, Squassina A, Stamm T, Stopkova P, Tortorella A, Turecki G, Vieta E, Veeh J, Witt S, Wright A, Zandi PP, Bauer M, Alda M, Rietschel M, McMahon FJ, Schulze TG, Baune BT.
    A polygenic score for Schizophrenia and HLA and inflammation genes predict response to lithium in Bipolar Affective Disorder.
    JAMA Psychiatry. 2018 Jan 1;75(1):65-74. doi: 10.1001/jamapsychiatry.2017.3433.

総説

  • 1. 石井 沙安也, 岡安 寛明, 下田 和孝.
    精神科薬物療法の実践と治療哲学 (第III章)<気分障害> 精神症状と間違えやすい副作用.
    臨床精神医学 (0300-032X)47巻増刊Page151-157(2018.12).

(分担執筆)

  • 1.岡安寛明.
    精神疾患 一般身体疾患による精神障害.
    今日の治療指針 2018年版. 医学書院 Page1005‐1006(2018.1).

2017年

原著(欧文)

  • 1. Watanabe T, Ueda M, Ishiguro S, Hayashi Y, Aoki A, Shinozaki M, Kato K, Akiyama K, Shimoda K.
    Early improvment and marriage are determinants of the 12-month treatment outcome of paroxetine in outpatients with panic disorder.
    Clinical Psychopharmacology and Neuroscience
    15(4):382-390、2017. doi: 10.9758/cpn.2017.15.4.382.
  • 2. Saito S, Fujii K, Ozeki Y, Ohmori K, Honda G, Mori H, Kato K, Kuroda J, Aoki A, Asahi H, Sato H, Shimoda K, Akiyama K.
    Cognitive function, treatment response to lithium, and social functioning in Japanese patients with bipolar disorder.
    Bipolar Disord. 2017 Nov;19(7):552-562. doi: 10.1111/bdi.12521. Epub 2017 Jul 10.
  • 3. Watanabe T, Ishiguro S, Aoki A, Ueda M, Hayashi Y, Akiyama K, Shimoda K.
    1019C/G (rs6295) promoter polymorphism of the 5-HT1A receptor G/G genotype is associated with panic disorder: an association study in a Japanese population Psychiatry Investigation  2017 Jan;14(1):86-92. doi: 10.4306/pi.2017.14.1.86. Epub 2016 Dec 29.

総説

  • 1. 尾関 祐二, 下田 和孝.
    統合失調症患者の死亡をいかに減らすか 薬剤選択においてどのように配慮すべきか.
    精神科 (1347-4790)31巻5号 Page481-485(2017.11).
  • 2. 藤井 久彌子, 尾関 祐二, 下田 和孝.
    高齢者に対する薬物療法.
    臨床精神薬理 (1343-3474)20巻10号 Page1103-1112(2017.10).
  • 3. 藤井 久彌子, 尾関 祐二, 下田 和孝.
    双極II型障害をどう診るか 双極II型障害と併存症.
    臨床精神医学 (0300-032X)46巻3号 Page317-323(2017.03).
  • 4. 篠.崎 將貴, 渡邊 崇, 下田 和孝.
    精神科領域の用語解説 ファーマコジェノミクス.
    分子精神医学 (1345-9082)17巻1号 Page48-50(2017.01).
  • 5. 佐伯吉規.
    緩和ケア口伝 現場で広がるコツとご法度 ケミカルコーピングにどう対応できるか-精神科医の立場から.
    緩和ケアプラス2 Page191-192(2017).

その他

  • 1.萩野谷 真人, 大曽根 彰, 下田 和孝.
    そこが知りたい薬物療法Q&A 軽度認知障害(MCI)に有効な薬物療法はあるか?
    臨床精神薬理 (1343-3474)20巻12号 Page1476-1480(2017.12).
  • 2.渡邊 崇, 下田 和孝.
    そこが知りたい薬物療法Q&A 抗うつ薬の自殺関連事象は治療初期に起こりやすいか?
    臨床精神薬理 (1343-3474)20巻10号 Page1181-1182(2017.10).
  • 3.竹内 祥貴, 尾関 祐二, 下田 和孝.
    そこが知りたい薬物療法Q&A COPD患者へのベンゾジアゼピン系薬剤使用について知りたい.
    臨床精神薬理 (1343-3474)20巻8号 Page923-925(2017.08).
  • 4.萩野谷 真人, 大曽根 彰, 下田 和孝.
    そこが知りたい薬物療法Q&A Memantineに気分安定作用があるのか?
    臨床精神薬理 (1343-3474)20巻6号 Page694-696(2017.06).
  • 5.渡邊 崇, 下田 和孝.
    そこが知りたい薬物療法Q&A Pregabalinに気分安定作用があるか?
    臨床精神薬理 (1343-3474)20巻4号 Page437-438(2017.04).
  • 6.川俣 安史, 尾関 祐二, 下田 和孝.
    そこが知りたい薬物療法Q&A 精神疾患にビタミンB12は有効か知りたい.
    臨床精神薬理 (1343-3474)20巻2号 Page207-208(2017.02).

2016年

原著(欧文)

  • 1. Hicks JK, Sangkuhl K, Swen JJ, Ellingrod VL, Müller DJ, Shimoda K, Bishop JR, Kharasch ED, Skaar TC, Gaedigk A, Dunnenberger HM, Klein TE, Caudle KE, Stingl JC.
    Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Tricyclic Antidepressants: 2016 Update.
    Clinical Pharmacology Therapeutics 2016 Dec 20. doi: 10.1002/cpt.597.
  • 2. Sugai T, Suzuki Y, Yamazaki M, Shimoda K, Mori T, Ozeki Y, Matsuda H, Sugawara N, Yasui-Furukori N, Minami Y, Okamoto K, Sagae T, Someya T.
    High prevalence of lifestyle-related disease in Japanese outpatients with schizophrenia: a nationwide survey.
    PLoS One. 2016 Nov 17;11(11):e0166429. doi: 10.1371/journal.pone.0166429. eCollection 2016.
  • 3. Akiyama K, Saito S, Saito A, Ozeki Y, Watanabe T, Fujii K, Honda G, Shimoda K.
    Predictive value of premorbid IQ, negative symptoms, and age for cognitive and social functions in Japanese patients with schizophrenia: A study using the Japanese version of the Brief Assessment of Cognition in Schizophrenia.
    Psychiatry Research 2016 Nov 1. pii: S0165-1781(16)30546-7. doi: 10.1016/j.psychres.2016.10.070. [Epub ahead of print].
  • 4. Nishimura M, Ueda M, Saruwatari J, Nakashima H, Ogusu N, Aoki A, Tsuchimine S, Matsuda K, Ono T, Oniki K, Shimoda K, Yasui-Furukori N.
    Different effects of cytochrome P450 2D6 genotypes on the pharmacokinetics of paroxetine in Japanese patients with major depressive disorder: A population pharmacokinetic analysis Pharmacogenetics and Genomics.
    Pharmacogenet Genomics. 2016 Sep;26(9):403-13. doi: 10.1097/FPC.0000000000000228
  • 5. Takano Y, Ozeki Y, Sekine M, Fujii K, Watanabe T, Okayasu H, Shinozaki T, Aoki A, Akiyama K, Homma H, Shimoda K.
    Multi-regression analysis revealed a relationship between l-serine and methionine, a component of one-carbon metabolism, in the normal control but not in the schizophrenia.
    Ann Gen Psychiatry. 2016 Aug 31;15(1):23. doi: 10.1186/s12991-016-0113-3. eCollection 2016.
  • 6. Osone A, Arai R, Hakamada R, Shimoda K.
    Cognitive and brain reserve in conversion and reversion in patients with mild cognitive impairment over 12 months of follow-up Journal of Clinical and Experimental Neuropsychology.
    J Clin Exp Neuropsychol. 2016 Jun 13:1-10. [Epub ahead of print]
  • 7. Nonaka-Hashida S, Sekine M, Ozeki Y, Fujii K, Akiyama K, Shimoda K, Tsunoda M, Katane M, Saitoh Y, Miyamoto T, Homma H.
    Plasma concentrations of three methylated arginines, endogenous nitric oxide synthase inhibitors, in schizophrenic patients under antipsychotic drug treatment.
    Psychiatry Res. 2016 Apr 30;238:203-10. doi: 10.1016/j.psychres.2016.02.029. Epub 2016 Feb 18.
  • 8. Ozeki Y, Sekine M, Fujii K, Watanabe T, Okayasu H, Takano Y, Shinozaki T, Aoki A, Aoki H, Mori H, Akiyama K, Homma H, Shimoda K.
    Phosphoserine phosphatase activity is elevated and negatively correlated with serum D-serine concentration in schizophrenia patients.
    Psychiatry Research 237: 344-350, 2016.
  • 9. Hou L, Heilbronner U, Degenhardt F, Adli M, Akiyama K, Akula N, Ardau R, Arias B, Backlund L, Banzato CE, Benabarre A, Bengesser S, Bhattacharjee AK, Biernacka JM, Birner A, Brichant-Petitjean C, Bui ET, Cervantes P, Chen GB, Chen HC, Chillotti C, Cichon S, Clark SR, Colom F, Cousins DA, Cruceanu C, Czerski PM, Dantas CR, Dayer A, Étain B, Falkai P, Forstner AJ, Frisén L, Fullerton JM, Gard S, Garnham JS, Goes FS, Grof P, Gruber O, Hashimoto R, Hauser J, Herms S, Hoffmann P, Hofmann A, Jamain S, Jiménez E, Kahn JP, Kassem L, Kittel-Schneider S, Kliwicki S, König B, Kusumi I, Lackner N, Laje G, Landén M, Lavebratt C, Leboyer M, Leckband SG, Jaramillo CA, MacQueen G, Manchia M, Martinsson L, Mattheisen M, McCarthy MJ, McElroy SL, Mitjans M, Mondimore FM, Monteleone P, Nievergelt CM, Nöthen MM, Ösby U, Ozaki N, Perlis RH, Pfennig A, Reich-Erkelenz D, Rouleau GA, Schofield PR, Schubert KO, Schweizer BW, Seemüller F, Severino G, Shekhtman T, Shilling PD, Shimoda K, Simhandl C, Slaney CM, Smoller JW, Squassina A, Stamm T, Stopkova P, Tighe SK, Tortorella A, Turecki G, Volkert J, Witt S, Wright A, Young LT, Zandi PP, Potash JB, DePaulo JR, Bauer M, Reininghaus EZ, Novák T, Aubry JM, Maj M, Baune BT, Mitchell PB, Vieta E, Frye MA, Rybakowski JK, Kuo PH, Kato T, Grigoroiu-Serbanescu M, Reif A, Del Zompo M, Bellivier F, Schalling M, Wray NR, Kelsoe JR, Alda M, Rietschel M, McMahon FJ, Schulze TG.
    Genetic variants associated with response to lithium treatment in bipolar disorder: a genome-wide association study.
    Lancet. 2016 Mar 12;387(10023):1085-93. doi: 10.1016/S0140-6736(16)00143-4. Epub 2016 Jan 22.
  • 10. Sugawara N, Yasui-Furukori N, Yamazaki M, Shimoda K, Mori T, Sugai T, Matsuda H, Suzuki Y, Minami Y, Ozeki Y, Okamoto K, Sagae T, Someya T.
    Attitudes toward metabolic adverse events among patients with schizophrenia in Japan.
    Neuropsychiatric Disease and Treatment 12 427–436, 2016.
  • 11. Sugai T, Suzuki Y, Yamazaki M, Shimoda K, Mori T, Ozeki Y, Matsuda H, Sugawara N, Yasui-Furukori N, Minami Y, Okamoto K, Sagae T, Someya T.
    Difference in prevalence of metabolic syndrome between Japanese outpatients and inpatients with schizophrenia: A nationwide survey.
    Schizophrenia Research 2016 Mar;171(1-3):68-73. doi: 10.1016/j.schres.2016.01.016. Epub 2016 Jan 22.

(和文)

  • 1.川俣 安史, 岡安 寛明,深堀 能立, 釜井 隆男, 下田 和孝.
    これでいいのか うつ病治療:どうしたらいい よくならない抑うつ症状I 小事例紹介:よくならない抑うつ症状をもつ人たち 抑うつ状態が難治しLate-onset hypogonadism症候群の診断に至った双極性障害の1例.
    精神科臨床サービス (1883-0463)16巻1号 Page80-83(2016.02).
  • 2.篠崎 隆央, 岡安 寛明, 下田 和孝.
    これでいいのか うつ病治療:どうしたらいい よくならない抑うつ症状I 小事例紹介:よくならない抑うつ症状をもつ人たち 繰り返す抑うつ症状に対して様々な治療的アプローチを試みた双極性障害の1例.
    精神科臨床サービス (1883-0463)16巻1号 Page77-79(2016.02).

総説

  • 1. 石川 高明, 篠崎 將貴, 下田 和孝.
    Venlafaxine遂に上陸 Venlafaxineの薬物動態.
    臨床精神薬理 (1343-3474)19巻4号 Page407-412(2016.04).

著書

  • 1.佐伯吉規.
    向精神薬の減量の仕方について教えてください.
    在宅訪問・かかりつけ薬剤師のための服薬管理 はじめの一歩コツとわざ.じほう.
    Page128-148(2016.8).
  • 2.尾関祐二,下田和孝.
    高次脳機能障害.
    看護学生のための神経内科学.中外医学者.Page100-106.(2016.2).

(翻訳)

  • 1.高橋三郎(監訳),下田和孝,大曽根彰(訳).
    DSM-5 ガイドブック -診断基準を使いこなすための指針.
    医学書院.(2016,6)ISBN:978-4-260-02486-0.

その他

  • 1. 萩野谷 真人, 大曽根 彰, 下田 和孝.
    そこが知りたい薬物療法Q&A Suvorexantは睡眠時無呼吸症候群に対して安全か?
    臨床精神薬理 (1343-3474)19巻12号 Page1733-1734(2016.12).
  • 2.渡邊 崇, 下田 和孝.
    そこが知りたい 薬物療法Q&A Gabapentinに気分安定作用があるか?
    臨床精神薬理 (1343-3474)19巻10号 Page1479-1480(2016.10).
  • 3.藤井 久彌子, 尾関 祐二, 篠崎 隆央, 下田 和孝.
    そこが知りたい薬物療法Q&A 統合失調症に、memantineは効果があるか.
    臨床精神薬理 (1343-3474)19巻8号 Page1169-1170(2016.08).
  • 4.萩野谷 真人, 大曽根 彰, 下田 和孝.
    そこが知りたい薬物療法Q&A Atomoxetineの投与により睡眠障害が改善されるか?
    臨床精神薬理 (1343-3474)19巻6号 Page821-822(2016.06).
  • 5.渡邊 崇, 下田 和孝.
    そこが知りたい薬物療法Q&A Topiramateに気分安定作用があるか?
    臨床精神薬理 (1343-3474)19巻4号 Page450-452(2016.04).
  • 6.篠崎 將貴, 尾関 祐二, 下田 和孝.
    そこが知りたい薬物療法Q&A Donepezilなどアセチルコリンエステラーゼ阻害薬は統合失調症の認知機能の改善に効果があるのか.
    臨床精神薬理 (1343-3474)19巻2号 Page203-205(2016.02).
  • 7.大曽根彰,下田和孝.
    獨協医科大学病院認知症疾患医療センターの活動状況.
    下都賀郡市医師会報 174:53-56(2016).

2015年

原著(欧文)

  • 1. Sugai T, Suzuki Y, Yamazaki M, Shimoda K, Mori T, Ozeki Y, Matsuda H, Sugawara N, Yasui-Furukori N, Minami Y, Okamoto K, Sagae T, Someya T.
    High prevalence of underweight and undernutrition in Japanese inpatients with schizophrenia : nationwide survey.
    BMJ Open 2015 Dec 9;5(12):e008720. doi: 10.1136/bmjopen-2015-008720.
  • 2. Osone A, Arai R, Hakamada R, Shimoda K.
    Impact of lifestyle-related disease on conversion and reversion in Japanese patients with mild cognitive impairment: 12 months of follow-up.
    International Journal of Geriatric Psychiatry 2016 Jul;31(7):740-8. doi: 10.1002/gps.4386. Epub 2015 Nov 22.
  • 3. Hayashi Y, Watanabe T, Aoki A, Ishiguro S, Ueda M, Akiyama K, Kato K, Inoue Y, Tsuchimine S, Yasui-Furukori N, Shimoda K.
    Factors affecting steady-state plasma concentrations of enantiomeric mirtazapine and its desmethylated metabolites in Japanese psychiatric patients.
    Pharmacopsychiatry 48:279-285, 2015.
  • 4. Gito M, Ihara H, Ogata H, Sayama M, Murakami N, Nagai T, Ayabe T, Oto Y, Shimoda K.
    Gender Differences in the Behavioural Symptom Severity of Prader-Willi Syndrome.
    Behavioural Neurology Volume 2015, Article ID 294127, 8 pages.
  • 5. Watanabe T, Hayashi Y, Aoki A, Ishiguro S, Ueda M, Akiyama K, Kato K, Inoue Y, Tsuchimine S, Yasui-Furukori N, Shimoda K.
    Impact of CYP2D6*10 polymorphism on the pharmacokinetics of mirtazapine and its desmethylated metabolite in Japanese psychiatric patients treated with mirtazapine.
    Clinical Neuropsychopharmacology and Therapeutics 6:5-15, 2015.
  • 6. Osone A, Arai, R, Hakamada, R, Shimoda K.
    Impact of cognitive reserve on the progression of mild cognitive impairment to Alzheimer’s disease in Japan.
    Geriatr Gerontol Int. 2015 Apr;15(4):428-34. doi: 10.1111/ggi.12292. Epub 2014 Apr 15.
  • 7. Song DK, Sawada M, Yokota S, Kuroda K, Uenishi H, Kanazawa T, Ogata H, Ihara H, Nagai T, Shimoda K.
    Comparative Analysis of Personality and Behavioral Disorders in Prader-Willi Syndrome and Asperger Disorder.
    American Journal of Medical Genetics 2015 Jan;167A(1):64-8. doi: 10.1002/ajmg.a.36787. Epub 2014 Nov 11.

(和文)

  • 1.小西 徹.
    心に残る症例 覚醒剤精神病の暴力団員との心理療法から見た精神科病院における多職種協働.
    精神科治療学 30巻6号 Page851-854(2015.6).

総説

  • 1. 石川 高明, 渡邊 崇, 下田 和孝.
    治療抵抗性うつ病の治療戦略 薬物代謝の観点から.
    臨床精神薬理 (1343-3474)18巻10号 Page1257-1262(2015.10).
  • 2. 藤井 久彌子, 尾関 祐二, 下田 和孝.
    向精神薬がもたらす身体合併症 向精神薬による循環器障害.
    日本医事新報 (0385-9215)4772号 Page31-36(2015.10).
  • 3. 渡邊 崇, 林 有希, 青木 顕子, 下田 和孝.
    うつ病に対する新しい治療の試み 欧米ですでに発売されている抗うつ薬とその特徴.
    精神科治療学 (0912-1862)30巻5号 Page581-586(2015.05).
  • 4. 石川 高明, 下田 和孝.
    エビデンスと実臨床との乖離をどう埋めるか うつ病治療に抗うつ薬の単剤治療は可能か SSRI・SNRIに非定型抗精神病薬や気分安定薬を併用するのは有益か?
    臨床精神薬理 (1343-3474)18巻3号 Page249-255(2015.03).

著書

  • 1.尾関祐二,下田和孝.
    精神症状・心理的問題が生じやすい身体疾患とその病態 腎疾患.
    精神科臨床エキスパートシリーズ 他科からの依頼情報の診方と仕方.医学書院.
    Page170-180(2015.5).
  • 2.渡邊崇,下田和孝.
    身体疾患治療薬と向精神薬との薬物相互作用.
    精神科臨床エキスパートシリーズ 他科からの依頼情報の診方と仕方.医学書院.
    Page230-236(2015.5).
  • 3.藤平明広,大曽根彰,下田和孝.
    腎機能障害患者.
    精神科臨床エキスパートシリーズ 精神科薬物治療-こんなときどうするべきか-.医学
    書院.Page154-165(2015.5).

(翻訳)

  • 1.高橋三郎(監訳),下田和孝,大曽根彰(訳).
    DSM-5鑑別診断ハンドブック.
    医学書院.(2015, 5) ISBN:978-4-260-02101-2.

その他

  • 1.下田和孝.
    第23回多文化間精神医学会を開催して.
    とちぎ精神衛生.42:12(2015.2016).
  • 2.藤平明広.
    平成28年熊本地震~DPAT獨協医科大学病院チーム活動報告.
    とちぎ精神衛生 42:18(2015・2016).
  • 3.萩野谷 真人, 大曽根 彰,下田 和孝.
    そこが知りたい薬物療法Q&A Aripiprazoleはせん妄に対して有効か?
    臨床精神薬理 (1343-3474)18巻12号 Page1574-1576(2015.12).
  • 4.渡邊 崇, 下田 和孝.
    そこが知りたい薬物療法Q&A Ramelteonはせん妄に対して有効か?
    臨床精神薬理 (1343-3474)18巻10号 Page1309-1310(2015.10).
  • 5.篠崎 隆央, 尾関 祐二, 下田 和孝.
    そこが知りたい 薬物療法Q&A Lithiumの攻撃性・衝動性に対する効果を知りたい.
    臨床精神薬理 (1343-3474)18巻8 Page1027-1028(2015.08).
  • 6.萩野谷 真人, 大曽根 彰, 下田 和孝.
    そこが知りたい薬物療法Q&A β遮断薬はPTSDに対して有効か?
    臨床精神薬理 (1343-3474)18巻6号 Page766-768(2015.06).
  • 7.渡邊 崇, 下田 和孝.
    そこが知りたい薬物療法Q&A Ramelteonは自閉性障害に伴う不眠に対して有効か?
    臨床精神薬理 (1343-3474)18巻4号 Page449-450(2015.04).
  • 8.高野 有美子, 尾関 祐二, 下田 和孝.
    そこが知りたい薬物療法Q&A Atomoxetineは抗うつ効果があるのかを知りたい.
    臨床精神薬理 (1343-3474)18巻2号 Page205-206(2015.02).

2014年

原著(欧文)

  • 1. Ishikawa T, Shinozaki T, Shimoda K.
    Rhabdomyolysis After the Administration of Clarithromycin in a Japanese Schizophrenic Patient Receiving Aripiprazole: A Possible Impact of CYP2D6 Genotype.
    Clinical Neuropsychopharmacology and Therapeutics 5:18:22, 2014.
  • 2. Aoki A, Ishiguro S, Watanabe T, Ueda M, Hayashi Y, Akiyama K, Kato K, Inoue Y, Tsuchimine S, Yasui-Furukori N, Shimoda K.
    Factors affecting discontinuation of initial treatment with paroxetine in panic disorder and major depressive disorder.
    Neuropsychiatr Dis Treat 2014 Sep 18;10:1793-8. doi: 10.2147/NDT.S68670. eCollection 2014.
  • 3. Nonaka S, Sekine M, Tsunoda M, Ozeki Y, Fujii K, Akiyamae K, Shimoda K, Furuchi T, Katane M, Saito Y, Homma H.
    Simultaneous determination of NG-monomethyl-L-arginine, NG,NG-dimethyl- L-arginine, and NG,NG’-dimethyl-L-arginine, and L-arginine using monolithic silica disk-packed spin columns and a monolithic silica column.
    Journal of Separation Science 2014 Aug;37(16):2087-94. doi: 10.1002/jssc.201400240. Epub 2014 Jun 30.
  • 4. Fujii K, Ozeki Y, Okayasu H, Takano Y, Shinozaki T, Hori H, Orui M, Horie M, Kunugi H, Shimoda K.
    QT is longer in drug-free patients with schizophrenia compared with age-matched healthy subjects.
    PLOS one 2014 Jun 2;9(6): e98555. doi: 10.1371/journal.pone.0098555. eCollection 2014.
  • 5. Okayasu H, Shinozaki T, Osone A, Ozeki Y, Shimoda K.
    Development of acute pancreatitis caused by sodium valproate in a patient with bipolar disorder on hemodialysis for chronic renal failure: a case report.
    BMC Psychiatry 2014 Mar 29; 14:93. doi: 10.1186/1471-244X-14-93.
  • 6. Sugawara N, Yasui-Furukori N, Yamzaki M, Shimoda K, Mori T, Sugai T, Suzuki Y, Someya T.
    Psychiatrists' attitudes toward metabolic adverse events in patients with schizophrenia
    Plos one 2014 Jan 23;9(1):e86826. doi: 10.1371/journal.pone.0086826. eCollection 2014.

(和文)

  • 1.近藤 年隆, 石川 高明, 尾関 祐二, 下田 和孝.
    薬剤調整を行ったことで修正型電気けいれん療法の効果が改善したうつ病の1症例.
    精神科 (1347-4790)25巻4号 Page461-464(2014.10).

総説

  • 1. 岡安 寛明, 尾関 祐二, 下田 和孝.
    向精神薬の副作用と対策 Update QT延長症候群ほかの不整脈.
    臨床精神医学 (0300-032X)43巻11号 Page1581-1584(2014.11).
  • 2. 青木 顕子, 渡邊 崇, 下田 和孝.
    身体疾患に併発した精神障害への薬物療法II 特に注意すべき抗精神病薬と一般治療薬の薬物相互作用.
    精神科治療学 (0912-1862)29巻4号 Page507-511(2014.04).
  • 3. 下田 和孝.
    診療の秘訣 季節性感情障害(冬季うつ病).
    Modern Physician (0913-7963)34巻4号 Page434(2014.04).
  • 4. 尾関 祐二, 藤井 久彌子, 下田 和孝.
    シンプル処方の極意 中等症から重症のうつ病におけるシンプル処方.
    臨床精神医学 (0300-032X)43巻1号 Page37-43(2014.01).
  • 5. 篠崎 隆央, 尾関 祐二, 下田 和孝.
    向精神薬の副作用モニタリング 向精神薬による電解質異常・腎機能障害のモニタリング. 臨床精神薬理 (1343-3474)17巻1号 Page57-62(2014.01).

著書

  • 1.渡邊崇,下田和孝.
    Ⅰ臨床薬理学総論 10 薬物有害反応.
    臨床精神神経薬理学テキスト 改訂第3版.星和書店 Page105-116(2014.11).
  • 2.近藤年隆,林有希,岡安寛明,下田和孝.
    第14章 抗うつ薬.
    類似薬の使い分け 改訂版.羊土社.Page251-261(2014.8).

その他

  • 1.萩野谷 真人, 大曽根 彰, 下田 和孝.
    そこが知りたい薬物療法Q&A 季節性感情障害に対して有効である薬物療法とは?
    臨床精神薬理 (1343-3474)17巻12号 Page1667-1669(2014.12).
  • 2.林 有希, 渡邊 崇, 下田 和孝.
    そこが知りたい薬物療法Q&A Mirtazapineの光学異性体であるS-(+)-mirtazapineは臨床上、有用か?
    臨床精神薬理 (1343-3474)17巻10号 Page1419-1420(2014.10).
  • 3.岡安 寛明, 尾関 祐二, 下田 和孝.
    そこが知りたい薬物療法Q&A 慢性腎不全のため透析している双極性障害患者に治療薬を選択する際の注意点を知りたい.
    臨床精神薬理 (1343-3474)17巻8号 Page1139-1141(2014.08).
  • 4.大曽根 彰, 藤平 明広, 下田 和孝.
    そこが知りたい薬物療法Q&A Lamotrigineによる造血障害のリスクについて知りたい. 臨床精神薬理 (1343-3474)17巻6号 Page843-845(2014.06).
    li 5.渡邊 崇, 下田 和孝.
    そこが知りたい薬物療法Q&A 異食症に対して有効な薬物療法は存在するのか?
    臨床精神薬理 (1343-3474)17巻4号 Page535-536(2014.04).
  • 6. 篠崎 隆央, 藤井 久彌子, 尾関 祐二, 下田 和孝.
    そこが知りたい薬物療法Q&A Lithiumによる体重増加について知りたい.
    臨床精神薬理 (1343-3474)17巻2号 Page217-218(2014.02).

2013年

原著(欧文)

  • 1. Kuratomi G, Saito A, Ozeki Y, Watanabe T, Fujii K, Shimoda K, Inukai T, Mori H, Ohmori K, Akiyama K.
    Association of the Hermansky--Pudlak syndrome type 4 (HPS4) gene variants with cognitive function in patients with schizophrenia and healthy subjects.
    BMC Psychiatry. 2013 Oct 30;13(1):276. [Epub ahead of print]
  • 2. Okayasu H, Ozeki Y, Chida M, Miyoshi S, Shimoda K.
    Lung transplantation in a Japanese patient with schizophrenia from brain-dead donor.
    General Hospital Psychiatry 102: e11-13, 2013
  • 3. Saito A, Kuratomi G, Ito C, Matsuoka H, Suzuki T, Ozeki Y, Watanabe T, Fujii K, Shimoda K, Fukushima Y, Inukai T, Ohmori K, Akiyama K.
    An association study of the Hermansky-Pudlak syndrome type 4 gene in schizophrenia patients.
    Psychiatric Genetics, 23:163-173, 2013.

2012年

原著(欧文)

  • 1. Okayasu H, Ozeki Y, Fujii K, Takano Y, Saeki Y, Hori H, Horie M, Higuchi T, Kunugi H, Shimoda K.
    Pharmachotherapeutic Determinants for QTc Interval Prolongation in Japanese Patients with Mood Disorder.
    Pharmacopsychiatry 47:279-283, 2012.

2011年

原著(欧文)

  • 1. Ishiguro S, Watanabe T, Ueda M, Saeki Y, Hayashi Y, Akiyama K, Saito A, Kato K, Inoue Y, Shimoda K.
    Determinants of pharmacodynamic trajectory of the therapeutic response to paroxetine in Japanese patients with panic disorder.
    European Journal of Clinical Pharmacology 67:1213-1221, 2011 DOI: 10.1007/s00228-011-1073-9.
  • 2. Akiyama K, Saito A, Shimoda K.
    Chronic methamphetamine psychosis after long-term abstinence in Japnese incarcerated patients. Ameircan Journal of Addiction 20: 240-249, 2011 10.1111/j.1521-0391.2011. 00124.x.
  • 3. Saito A, Fujikura-Ouchi Y, Ito C, Matsuoka H, Shimoda K, Akiyama K.
    An association study on polymorphisms in the PEA15, ENTPD4 and GAS2L1 genes and schizophrenia.
    Psychiatry Research 185:9-15, 2011.

2010年

原著(欧文)

  • 1. Takahashi M, Hayashi H, Watanabe Y, Sawamura K, Fukui N, Watanabe J, Kitajima T, Yamanouchi Y, Iwata N, Mizukami K, Hori T, Shimoda K, Ujike H, Ozaki N, Iijima K, Takemura K, Aoshima H, Someya T.
    Diagnostic classification of schizophrenia by neural network analysis of blood-based gene expression signatures.
    Schizophrenia Research 119:210-218, 2010, E-pub ahead of print doi: 10.1016/j.schres.2009.12.024.
  • 2. Morita S, Roh HK, Shimoda K, Someya T, Shibasaki M, Hirokane G, Svensson JO, Bertilsson L.
    A comparison of haloperidol plasma levels among Japanese, Korean and Swedish psychiatric patients.
    Clinical Neuropsychopharmacology and Therapeutics 1:24-30, 2010.

2009年

原著(欧文)

  • 1. Saeki Y, Watanabe T, Ueda M, Saito A, Akiyama K, Inoue Y, Hirokane G, Morita S, Yamada N, Shimoda K.
    Genetic and pharmacokinetic factors affecting the initial pharmacotherapeutic effect of paroxetine in Japanese patients with panic disorder.
    European Journal of Clinical Pharmacology 65(7):685-91, 2009

2007年

原著(欧文)

  • 1. Watanabe T, Ueda M, Saeki Y, Hirokane G, Morita S, Okawa M, Akiyama K, Shimoda K.
    High plasma concentrations of paroxetine impede clinical response in patients with panic disorder. Therapeutic Drug Monitoring 29(1):40-44, 2007.

2006年

原著(欧文)

  • 1. Saito A, Fujikura-Ouchi Y, Kuramasu A, Shimoda K, Akiyama K, Matsuoka H, Ito C.
    Association study of putative promoter polymorphisms in the neuroplastin gene and schizophrenia. Neuroscience Letter 411(3):168-73, 2006.
  • 2. Ueda M, Hirokane G, Morita S, Okawa M, Watanabe T, Akiyama K, Shimoda K.
    The impact of CYP2D6 genotypes on the plasma concentration of paroxetine in Japanese psychiatric patients.
    Progress in Neuropsychopharmacology & Biological Psychiatry;30(3):486-91, 2006.